About Covidien (NYSE:COV)
Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company’s brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company’s segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company’s products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
Industry, Sector and Symbol
Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity20.06%
Return on Assets9.92%
Covidien (NYSE:COV) Frequently Asked Questions
What is Covidien's stock symbol?
Covidien trades on the New York Stock Exchange (NYSE) under the ticker symbol "COV."
How were Covidien's earnings last quarter?
Covidien Ltd (NYSE:COV) announced its earnings results on Wednesday, November, 5th. The healthcare company reported $1.15 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.02 by $0.13. The healthcare company earned $2.73 billion during the quarter, compared to analyst estimates of $2.69 billion. Covidien had a net margin of 19.02% and a return on equity of 20.06%. The company's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.91 EPS. View Covidien's Earnings History.
Who are some of Covidien's key competitors?
Some companies that are related to Covidien include Baxter International (BAX), C.R. Bard (BCR), Zimmer Biomet (ZBH), Align Technology (ALGN), DENTSPLY SIRONA (XRAY), Bio-Rad Laboratories (BIO), Steris (STE), West Pharmaceutical Services (WST), Hill-Rom (HRC), DexCom (DXCM), VWR (VWR), ICU Medical (ICUI), LivaNova (LIVN), Integra LifeSciences (IART), Globus Medical (GMED), Neogen (NEOG), Haemonetics (HAE) and NuVasive (NUVA).
Who are Covidien's key executives?
Covidien's management team includes the folowing people:
- Gary L. Ellis, President, Chief Executive Officer (Age 60)
- Charles J. Dockendorff, Chief Financial Officer, Executive Vice President (Age 62)
- Bryan C. Hanson, Group President, Covidien (Age 50)
- John H. Masterson, Senior Vice President, General Counsel (Age 54)
- Michael P. Dunford, Senior Vice President - Human Resources (Age 54)
- James C. Clemmer, Senior Vice President and President - Medical Supplies Business (Age 53)
- Amy A. McBride-Wendell, Senior Vice President - Strategy and Business Development (Age 53)
- Jacqueline F. Strayer, Senior Vice President-Corporate Communications (Age 58)
- Michael E. Tarnoff, Senior Vice President,Chief Medical Officer (Age 46)
- Peter L. Wehrly, Senior Vice President, Group President - Developed Markets (Age 57)
How do I buy Covidien stock?
Shares of Covidien can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Covidien's stock price today?
One share of Covidien stock can currently be purchased for approximately $0.04.
How big of a company is Covidien?
Covidien has a market capitalization of $48.98 billion.
How can I contact Covidien?
Covidien's mailing address is 20 On Hatch Lower Hatch Street, Dublin 2, DUBLIN,, Ireland. The healthcare company can be reached via phone at +353-1-4381700.
MarketBeat Community Rating for Covidien (COV)MarketBeat's community ratings are surveys of what our community members think about Covidien and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Covidien (NYSE:COV) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Covidien (NYSE:COV) Earnings History and Estimates Chart
Covidien (NYSE COV) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/22/2015||Q115||$1.04||$1.11||$2.72 billion||$2.69 billion||View||N/A|
|11/5/2014||Q414||$1.02||$1.15||$2.69 billion||$2.73 billion||View||Listen|
|7/25/2014||Q314||$1.00||$1.04||$2.69 billion||$2.69 billion||View||Listen|
|4/25/2014||Q214||$0.95||$0.96||$2.61 billion||$2.60 billion||View||Listen|
|1/24/2014||Q114||$0.94||$1.00||$2.61 billion||$2.64 billion||View||Listen|
|8/1/2013||Q3 2013||$0.89||$0.85||$2.58 billion||$2.58 billion||View||Listen|
|4/26/2013||Q2 2013||$1.09||$1.12||$3.12 billion||$3.10 billion||View||Listen|
|1/25/2013||Q1 2013||$1.06||$1.10||$3.00 billion||$3.06 billion||View||Listen|
|11/9/2012||Q412||$1.00||$1.02||$2.98 billion||$3.00 billion||View||N/A|
Covidien (NYSE:COV) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Covidien (NYSE:COV) Dividend Information
|Most Recent Dividend:||1/16/2015|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||0.00% (Trailing 12 Months of Earnings) |
|Track Record:||8 Years of Consecutive Dividend Growth|
Covidien (NYSE:COV) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Covidien (NYSE COV) Insider Trading and Institutional Ownership History
Covidien (NYSE COV) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/5/2014||Michael Sgrignari||SVP||Sell||25,795||$103.48||$2,669,266.60|| |
|12/3/2014||Dennis H Reilley||Director||Sell||10,521||$101.39||$1,066,724.19|| |
|11/17/2014||Richard G Brown Jr||VP||Buy||5,300||$94.44||$500,532.00|| |
|11/7/2014||Robert H Brust||Director||Sell||4,000||$92.03||$368,120.00|| |
|8/27/2014||Coleman N Lannum III||VP||Buy||3,338||$87.23||$291,173.74|| |
|8/26/2014||Coleman N Lannum III||VP||Buy||1,736||$87.46||$151,830.56|| |
|8/19/2014||Coleman N Lannum III||VP||Buy||1,720||$87.82||$151,050.40|| |
|8/18/2014||Coleman N Lannum III||VP||Buy||4,100||$87.58||$359,078.00|| |
|6/16/2014||Jose E Almeida||Insider||Sell||51,166||$92.05||$4,709,830.30|| |
|4/29/2014||Brian Douglas King||VP||Sell||15,569||$70.11||$1,091,542.59|| |
|3/28/2014||Charles Dockendorff||CFO||Sell||90,730||$72.50||$6,577,925.00|| |
|2/28/2014||Jose Almeida||Insider||Sell||50,000||$72.00||$3,600,000.00|| |
|2/13/2014||Richard Brown, Jr.||VP||Sell||4,000||$71.00||$284,000.00|| |
|2/11/2014||Brian Douglas King||VP||Sell||17,946||$70.00||$1,256,220.00|| |
|2/11/2014||Bryan Hanson||SVP||Sell||32,480||$69.97||$2,272,625.60|| |
|1/29/2014||Coleman Lannum III||VP||Sell||13,787||$69.23||$954,474.01|| |
|1/24/2014||Richard Brown, Jr.||VP||Sell||4,000||$70.00||$280,000.00|| |
Covidien (NYSE COV) News Headlines
Covidien (NYSE:COV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Covidien (NYSE:COV) Income Statement, Balance Sheet and Cash Flow Statement
Covidien (NYSE COV) Stock Chart for Thursday, December, 14, 2017